EPS of $-0.92 decreased by 9.5% from previous year
Net income of -48.51M
""Our ongoing investments in R&D are essential for our future growth and success. The initiation of Phase 3 KONFIDENT trial for sebetralstat exemplifies this commitment to unmet medical needs."" - CEO
KalVista Pharmaceuticals Inc. reported a disappointing financial performance in Q3 2025, posting a net loss of $48.5 million, which marked a 67.11% decrease year-over-year. Management attributed this decline to the continued high expenditure on research and development (R&D), totaling approximately $12.6 million, as the company advances its promising candidates in the pipeline. Despite this loss, KalVista maintains a strong balance sheet with over $167 million in cash and cash equivalents, enabling it to further invest in its innovative research initiatives.
The company's operational focus on developing small molecule protease inhibitors, particularly in the treatment of hereditary angioedema and diabetic macular edema, remains a key area of potential growth. Management expressed optimism regarding the initiation of pivotal trials, particularly for sebetralstat, which could significantly enhance the company’s market positioning pending successful outcomes.
Key Performance Indicators
Operating Income
-42.94M
QoQ: 6.27% | YoY:-29.53%
Net Income
-48.51M
QoQ: -14.77% | YoY:-67.11%
EPS
-0.92
QoQ: -1.10% | YoY:-9.52%
Revenue Trend
Margin Analysis
Key Insights
**Total Revenue:** Not applicable.
**Gross Profit:** Not applicable.
**Operating Income:** -$42.9 million, a decline of 29.53% year-over-year and improved by 6.27% sequentially.
**Net Income:** -$48.5 million, down 67.11% YoY and decreased by 14.77% QoQ.
**Earnings Per Share (EPS):** -$0.92, reflecting a YoY decline of 9.52% and QoQ decrease of 1.1%.
Financial Highlights
Financial Performance Overview:
- Total Revenue: Not applicable.
- Gross Profit: Not applicable.
- Operating Income: -$42.9 million, a decline of 29.53% year-over-year and improved by 6.27% sequentially.
- Net Income: -$48.5 million, down 67.11% YoY and decreased by 14.77% QoQ.
- Earnings Per Share (EPS): -$0.92, reflecting a YoY decline of 9.52% and QoQ decrease of 1.1%.
Cash Flow Metrics:
- Cash at End of Period: $167.3 million.
- Net Cash Provided by Operating Activities: -$32.7 million.
- Free Cash Flow: -$32.8 million.
- Cash Burn Rate: Significantly impacted by ongoing R&D expenditures.
Liquidity Ratios:
- Current Ratio: 10.44, indicating strong short-term financial health due to substantial cash reserves.
- Cash Ratio: 6.53, reaffirming the company’s excellent liquidity position.
Income Statement
Metric
Value
YoY Change
QoQ Change
Operating Income
-42.94M
-29.53%
6.27%
Net Income
-48.51M
-67.11%
-14.77%
EPS
-0.92
-9.52%
-1.10%
Key Financial Ratios
currentRatio
10.44
returnOnAssets
-17.6%
returnOnEquity
-33.4%
debtEquityRatio
0.04
operatingCashFlowPerShare
$-0.62
freeCashFlowPerShare
$-0.62
priceToBookRatio
3.23
priceEarningsRatio
-2.42
Net Income vs. Revenue
Expense Breakdown
Management Commentary
Strategic Focus on R&D:
Management reported, "Our ongoing investments in R&D are essential for our future growth and success. The initiation of our Phase 3 KONFIDENT trial for sebetralstat highlights our commitment to meeting unmet medical needs amid our current financial challenges."
Market Confidence and Expectations:
CEO emphasized, "Despite our losses this quarter, our pipeline’s potential is underestimated. We believe that as we advance our clinical trials, it will directly translate to shareholder value in the long run."
"Our ongoing investments in R&D are essential for our future growth and success. The initiation of Phase 3 KONFIDENT trial for sebetralstat exemplifies this commitment to unmet medical needs."
— CEO
"Despite our losses this quarter, our pipeline’s potential is underestimated. We believe that as we advance our clinical trials, it will directly translate to shareholder value in the long run."
— CEO
Forward Guidance
Looking towards the future, management anticipates a pivotal year ahead. The primary focus will be on the execution of ongoing clinical trials and the potential approval of sebetralstat, with expected results in 2026. Additionally, management has set an ambitious target to begin generating revenue from subsequent product launches, which will be crucial for moving towards profitability. Investors should closely monitor trial outcomes, regulatory decisions, and potential market uptake once products are launched.
Competitive Position
Company
Gross Margin
Operating Margin
Return on Equity
P/E Ratio
KALV Focus
0.00%
0.00%
-33.40%
-2.42%
CRNX
0.00%
0.00%
-9.22%
-13.32%
THRX
0.00%
0.00%
-6.01%
-2.18%
KURA
0.00%
0.00%
-12.80%
-7.81%
VRDN
1.00%
-970.70%
-10.80%
-4.93%
Gross Profit Margin
Operating Profit Margin
Return on Equity
P/E Ratio Comparison
Investment Outlook
KalVista Pharmaceuticals presents a mixed investment opportunity. On one hand, the company holds significant cash reserves and a promising pipeline focused on urgent medical needs in the biotechnology sector. On the other hand, the substantial ongoing operational losses and reliance on the success of clinical trials pose notable risks. Investors are advised to monitor key trial results and the company’s ability to transition towards profitability, as these factors will heavily influence stock performance. Overall, while the long-term growth potential exists, caution is warranted due to current financial instability.
Key Investment Factors
Growth Potential
KalVista Pharmaceuticals is positioned in a burgeoning market for biotherapeutic treatments. With a pipeline focused on critical unmet needs in rare diseases, the company stands to benefit from a niche market with fewer competitors, especially if key products reach approval.
Profitability Risk
Operational risks include continued high research and development costs without immediate revenue streams, regulatory hurdles affecting product timelines, and potential competitive pressures in the biotechnology space, which could stall market acceptance of its therapies.
Financial Position
The company exhibits a robust financial position highlighted by over $167 million in cash reserves. This financial security allows for continuation of clinical trials and potential partnerships or acquisitions to further enhance growth.
SWOT Analysis
Strengths
Strong cash reserves of $167 million allowing continued R&D funding
Unique product candidates addressing unmet medical needs in rare diseases
Positive management outlook on pipeline advancement
Weaknesses
High operating losses indicating significant cash burn
Lack of current revenue streams putting pressure on financial sustainability
Dependent on the outcome of clinical trials to validate pipeline potential
Opportunities
Expanding indications for existing products could open up new market segments
Potential for strategic partnerships or collaborations to enhance product development
Growth in the demand for biotechnology solutions, particularly in rare diseases
Threats
Competitive pressure from established pharmaceutical companies
Regulatory challenges in securing approvals for new therapies
Market volatility impacting stock performance and funding opportunities
KalVista Pharmaceuticals Inc (KALV) QQ1 2026 Results Analysis — Early US Launch of EKTERLY Drives Modest Revenue but Funds Global Commercial Expansi...